Figure 5.

CD8⁺ T cells migrated to the tumor microenvironment and significantly suppressed tumor growth in the A549-derived tumor xenografts co-injected with healthy PBMCs and A549 cells. (A) A549 cells (2 × 10⁶) were injected subcutaneously into the right legs of mice (Tumor 1 (T1) to T4), and after the tumor grew up 100 mm³, the PBMCs (1 × 10⁷) alone or with A549 or PC9 (2 × 10⁵) were injected into the left for 48 h circulation. ¹¹¹In-labeled nivolumab was injected into the mice and the radioactive signals were measured in 3, 24, and 48 h. Tumors are indicated by arrows. (B) Quantification for the radioactive signals of 24 h in the T1 to T4 tumors was measured based on an 8μCi calibrated standard. (C) Meanwhile, the tumor volumes in T1 to T4 were recorded and compared. Tumors are indicated by arrows. n = 3 for each group.